A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
NCT05464719
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Large B-cell Lymphoma
Lymphoma
Interventions
DRUG:
Loncastuximab Tesirine
Sponsor
M.D. Anderson Cancer Center